[ad_1]
The researcher at the Oswaldo Cruz Foundation (Fiocruz), Júlio Croda, said today that the approval in the United Kingdom of the vaccine developed by the University of Oxford and the pharmaceutical group AstraZeneca can accelerate the vaccination process in Brazil against the coronavirus.
Yesterday, the CEO of the company, Pascal Soriot, said that the vaccine should be approved “before Thursday 1 January” by the United Kingdom.
“With approval in England, probably the same documentation, which was submitted to the British regulatory agency, will be sent to Anvisa, no later than 15 days. So we can anticipate, instead of February, even start vaccination earlier, if you have a dose available. That is good news, “said Croda, in an interview with” Urgent Brasil. “
The immunizing agent is the federal government’s main bet to combat the covid-19 pandemic. Fiocruz intends to deliver 210.4 million doses in the country throughout 2021, enough to vaccinate more than 105 million people.
The idea of taking the request to the National Health Surveillance Agency (Anvisa) between the end of 2020 and the beginning of the following year had already been announced by Fiocruz and cited by the Ministry of Health.
“May have approval before doses [chegarem ao Brasil]. And we can work on this expectation at the end of January, beginning of February, depending on the arrival of the vaccine ”, added the researcher.
Still according to Croda, he is capable of both the AstraZeneca and CoronaVac vaccines, from the São Paulo government, being approved at the same time by Anvisa.
